Get started

Amgen

Amgen's MariTide Shakes Up Weight Loss Drug MarketThe weight loss drug market, projected to hit $100 billion by the decade's end, is undergoing significant innovation. Amidst dominant players like Novo Nordisk and Eli Lilly, Amgen is emerging with MariTide, a potentially game-changing drug set to disrupt the industry. MariTide's extended-release formula promises reduced dosing frequency and sustained weight loss, potentially outperforming current medications. Amgen's advantage lies in its robust manufacturing infrastructure, enabling efficient scaling compared to smaller competitors. However, the field is crowded, with Novo Nordisk and Eli Lilly developing next-gen drugs, while Boehringer Ingelheim and others introduce new contenders. Smaller biotechs like Viking Therapeutics and Altimmune are also advancing innovative solutions. This competitive landscape promises diverse and effective weight management options for patients. The future looks bright, with Amgen positioned as a strong buy in this evolving market.
NASDAQ:AMGNLong
by signalmastermind
AMGN Rises as CEO Celebrates Growth in Experimental Obesity DrugAmgen Inc.'s shares ( NASDAQ:AMGN ) rose by 15.9% when the market opened on Friday, marking its biggest intraday rise since July 2009. The company has emerged as a potential competitor to Eli Lilly & Co. and Novo Nordisk A/S, which currently dominate the weight-loss market. Demand for anti-obesity drugs like Zepbound and Wegovy is so strong that Intelligence's estimate for $80 billion in annual sales by 2030 looks conservative. William Blair analyst Matt Phipps sees MariTide as having multi-blockbuster potential, boosting his rating on Amgen stock to outperform. Shares of Denmark's Novo Nordisk fell as much as 5.3% after the Amgen CEO's comments. Optimism over towering sales of its Wegovy and Ozempic drugs have pushed Novo's market value above $500 billion, reinforcing its position as Europe's most valuable listed company. The stock has more than quadrupled since the start of 2020. MariTide has excited investors because it's taken less frequently than the top-selling treatments from Novo and Lilly. Patients given a monthly injection of the drug lost up to 14.5% of their body weight in 12 weeks, according to a small early-stage study published in February in the journal Nature Metabolism. Some people kept weight off for up to 150 days after stopping the drug, the findings showed. Amgen ( NASDAQ:AMGN ) is already investing in building out production capacity for MariTide, even though it's still in mid-stage studies and hasn't been submitted for regulatory approval. Amgen is planning late-stage studies in obesity, obesity-related conditions, and diabetes, likely delivered in a handheld autoinjector used monthly. Amgen will focus on MariTide and discontinue developing another earlier-stage drug called AMG 786.
NASDAQ:AMGNLong
by DEXWireNews
AMGN Amgen Options Ahead of Earnings If you haven`t sold AMGN on the HZNP deal: Then analyzing the options chain and the chart patterns of AMGN Amgen prior to the earnings report this week, I would consider purchasing the 262.5usd strike price Puts with an expiration date of 2023-11-17, for a premium of approximately $8.15. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NASDAQ:AMGNShort
by TopgOptions
AMGEN Short-term buy signalAmgen Inc (AMGN) broke above the quick Bull Flag pattern and is targeting the top of the Channel Down pattern at 277.00. Based on the 1D MACD, this is a symmetrical bullish sequence as the one that peaked in early November. That will be a major test for the uptrend as the longer the price stays high, the easier it will form a 1D Golden Cross, the first since February 22 2023. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:AMGNLong
by TradingShot
1
AMGN Amgen to buy HZNP for $27.8 BillionAMGN Amgen to buy HZNP Horizon Therapeutics for about $27.8 billion. This huge spend could trigger a selloff in AMGN Amgen stock after earnings. It`s speculative, but looking at the AMGN Amgen options chain ahead of earnings , I would buy the $240 strike price Puts with 2023-2-17 expiration date for about $2.75 premium. If the options turn out to be profitable Before the earnings release, I would sell at least 50%. Looking forward to read your opinion about it.
NASDAQ:AMGNShort
by TopgOptions
3
AMGN: A High Probability Buy Setup Amgen Inc. has been trending up since December last year. We can observe that price has recently reached a higher high at the resistance level of 258.00. Therefore, we are only looking for buy entries for this stock. 258.00 is a very strong resistance level; we can see from the past that prices have rejected more than 9 times from this level. After rejections, prices retraced but eventually rose again to retest this level multiple times. Last week, price gapped down from this resistance level, dropping back to the trend line. Therefore, this gives us a great opportunity to buy the pullback. Entry Criteria: We can observe from the past price movement that when the price touched the current ascending trend line, a gap up immediately was formed, followed by a strong bullish momentum sending the price back to the previous high. Therefore, during the next few days, we will be looking for a gap up from the trend line. Then we will place our buy stop orders to capture the bullish momentum. This is a high probability buy setup because many factors support another bullish impulsive movement which could potentially send the price back to retest the recent high.
NASDAQ:AMGNLong
by NicoBeau_Capital
Bearish on Amgen. AMGNImmediate targets 211, 200,186. Invalidation at 279. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NASDAQ:AMGNShort
by Rykin_Capital
Amgen might move down soon according to the RSI....I have changed up how to best display projected movement. In the case of AMGN triggered a SELL on my RSI algorithm on March 19, 2021. Equities nearly always obey the signal and move down, but sometimes it may continue to move up first. I have placed two red boxes and two green boxes on the chart. The larger red box depicts all of the historical movement, from a percentage standpoint, that this stock has moved on the Daily chart after a SELL signal occurred. Therefore, this box represents 100% of previous movement upward before the stock finally moved downward. The smaller red box represents 50% of all historical movement upward, before the stock moved downward. The smaller box is more of a precise target for the potential top in this instance. The green boxes represent the same thing. In this instance, the smaller green box would be my projected target for the final bottom. The black dotted arrow represents median historical movement. Medians are a good metric, but they are just one of many I use when forecasting future movement. As always, the stock could decline the very next bar after the signal without looking back (therefore the red boxes would not come into play) or the stock may never decline (and the green boxes may never come into play). All statistics and the full analysis are available for free as always at the site below.
NASDAQ:AMGNShort
by StockSignaler
$AMGN - NR Picks Nov 22Amgen se dedica a descubrir, desarrollar, fabricar y ofrecer terapias humanas en todo el mundo. Se centra en las áreas de inflamación, oncología / hematología, salud ósea, enfermedades cardiovasculares, nefrología y neurociencia. La compañía tuvo una reacción positiva a inicios de mes cuando presentó una actualización de su fármaco para la psoriasis, durante el mes el precio de la acción fue cayendo hasta estar cerca a los niveles pre-reacción. Este retroceso se ve como una oportunidad para Amgen , recordemos que esta compañía es una de las mas importantes del sector. Creemos que el interés de los inversores durante el mes ha cambiado a compañías que están brindando actualizaciones sobre el desarrollo de la vacuna contra el COVID-19.
NASDAQ:AMGNLong
by NewroadTrader